Allogene Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic CAR T therapies for cancer, announced that the US FDA has granted ODD to ALLO-715 for the treatment of MM.
[Allogene Therapeutics, Inc.]
7992332
{7992332:nan}
apa
50
1
165662
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/